Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01QKZ
|
|||
| Former ID |
DIB012673
|
|||
| Drug Name |
ABT-413
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Spectrin non-erythroid beta chain 1 (SPTBN1) | Target Info | . | [2] |
| Pathway Interaction Database | TGF-beta receptor signaling | |||
| Reactome | Nephrin interactions | |||
| NCAM signaling for neurite out-growth | ||||
| Interaction between L1 and Ankyrins | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| TGF beta Signaling Pathway | ||||
| Nephrin interactions | ||||
| NCAM signaling for neurite out-growth | ||||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035144) | |||
| REF 2 | The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. International Journal of Medicinal Chemistry Volume 2011 (2011), Article ID 424535, Page(8). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.